The Chemours Company (NYSE:CC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of The Chemours Company (NYSE:CC) have received an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $24.10.

Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Chemours from $17.00 to $21.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Alembic Global Advisors reiterated an “overweight” rating and set a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. Royal Bank Of Canada increased their price target on Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. UBS Group raised their price objective on Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Zacks Research upgraded Chemours from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st.

Chemours Stock Up 0.2%

CC stock opened at $17.25 on Monday. The stock has a market capitalization of $2.59 billion, a P/E ratio of -6.53 and a beta of 1.41. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The firm has a 50-day moving average price of $20.35 and a 200-day moving average price of $19.92.

Chemours (NYSE:CC) last announced its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.10. The company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 EPS. As a group, equities research analysts anticipate that Chemours will post 1.18 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is presently -13.26%.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Baird Financial Group Inc. bought a new position in Chemours in the 1st quarter valued at approximately $148,000. Royal Bank of Canada grew its holdings in Chemours by 6.8% during the 1st quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock worth $7,926,000 after acquiring an additional 37,382 shares during the last quarter. AQR Capital Management LLC bought a new stake in Chemours during the 1st quarter worth approximately $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Chemours by 149.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock valued at $593,000 after acquiring an additional 25,899 shares during the period. Finally, Empowered Funds LLC acquired a new position in Chemours in the 1st quarter valued at approximately $403,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.